Reported a net loss of $822,996 for the three months ended March 31, 2026, compared to a loss of $476,094 in the same period of 2025. Operating expenses increased to $822,701, driven primarily by higher research and development costs ($331,513) and general and administrative expenses ($396,798). Cash balance decreased to $714,341 as of March 31, 2026, from $1,436,928 at the end of 2025. The company remains in the development stage with no revenue generated during the quarter. Working capital is reported at $751,663, with management noting sufficient funds for approximately four months of operations.